Read by QxMD icon Read

astra zeneca

Marilene Lopes Ângelo, Fernanda de Lima Moreira, André Luís Morais Ruela, Ana Laura Araújo Santos, Hérida Regina Nunes Salgado, Magali Benjamim de Araújo
Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. This drug is indicated for dyslipidemias treatment and can help to decrease the level of "bad cholesterol" and can consequently reduce the development of atherosclerosis and the risk of heart diseases. ROS was developed by Astra-Zeneca and it was approved in 2003 by the FDA in the United States. In 2015, under the trade name Crestor®, it was the fourth largest selling drug in the United States with sales above $5 billion...
March 13, 2018: Critical Reviews in Analytical Chemistry
R Y Ateser, N Kayacan
OBJECTIVE: The aim of the present study was to evaluate the optimum dose of ropivacaine by comparing three different dosing regimens of isobaric ropivacaine 1% (naropin 10 mg/ml, Astra Zeneca) administered intrathecally and to demonstrate the effects of anesthesia in pregnant women scheduled for cesarean section. PATIENTS AND METHODS: Sixty ASA grade I-II patients were scheduled to undergo elective cesarean sections under spinal anesthesia. The patients were randomly assigned into three groups...
October 2017: Nigerian Journal of Clinical Practice
Payam Dehghani, Andrea Lavoie, Shahar Lavi, Jennifer J Crawford, Sebastian Harenberg, Rodney H Zimmermann, Jeff Booker, Sheila Kelly, Warren J Cantor, Shamir R Mehta, Akshay Bagai, Shaun G Goodman, Asim N Cheema
OBJECTIVES: Patients undergoing PCI early after fibrinolytic therapy are at high risk for both thrombotic and bleeding complications. We sought to assess the pharmacodynamic effects of ticagrelor versus clopidogrel in the fibrinolytic-treated STEMI patients undergoing early PCI. METHODS AND RESULTS: Patients undergoing PCI within 24 hours of tenecteplase (TNK), aspirin, and clopidogrel for STEMI were randomized to receive additional clopidogrel 300 mg followed by 75 mg daily or ticagrelor 180 mg followed by 90 mg twice daily...
October 2017: American Heart Journal
Wim H Winthorst, Annelieke M Roest, Elisabeth H Bos, Ybe Meesters, Brenda W J H Penninx, Willem A Nolen, Peter de Jonge
BACKGROUND: Seasonal affective disorder (SAD) is considered to be a subtype of depression. AIMS: To compare the clinical picture of SAD to non-seasonal affective disorders (non-SADs). METHOD: Diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) were established in 2185 participants of the Netherlands Study of Depression and Anxiety. The Seasonal Pattern Assessment Questionnaire was administered to diagnose SAD...
July 2017: BJPsych Open
Stefano Genovese, Edoardo Mannucci, Antonio Ceriello
INTRODUCTION: Exenatide once weekly (ExeOW, Bydureon ® , Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, is the first agent approved for treatment of type 2 diabetes (T2D) that can be administered on a weekly basis. METHODS: Data concerning treatment of T2D with ExeOW are reviewed with special reference to its long-term efficacy, tolerability, and safety. Relevant literature was identified through the PubMed database from inception to January 2015...
August 2017: Advances in Therapy
Rebecca J Brown, David Araujo-Vilar, Pik To Cheung, David Dunger, Abhimanyu Garg, Michelle Jack, Lucy Mungai, Elif A Oral, Nivedita Patni, Kristina I Rother, Julia von Schnurbein, Ekaterina Sorkina, Takara Stanley, Corinne Vigouroux, Martin Wabitsch, Rachel Williams, Tohru Yorifuji
OBJECTIVE: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. PARTICIPANTS: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts...
December 2016: Journal of Clinical Endocrinology and Metabolism
C J Musante, S Ramanujan, B J Schmidt, O G Ghobrial, J Lu, A C Heatherington
Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model-informed drug discovery and development, supporting program decisions from exploratory research through late-stage clinical trials. In this commentary, we discuss the unique value of disease-scale "platform" QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.
January 2017: Clinical Pharmacology and Therapeutics
John Reynolds, David Ray, M Yvonne Alexander, Ian Bruce
BACKGROUND: Patients with systemic lupus erythematosus (SLE) have endothelial dysfunction and increased risk of cardiovascular disease. Endothelium-dependent dilatation (ED) is abnormal in patients with SLE, and endothelial repair mechanisms are also impaired. Myeloid angiogenic cells (MACs) promote angiogenesis to restore damaged vessels. Vitamin D deficiency is associated with cardiovascular disease in the general population and is prevalent in SLE. We aimed to assess the effect of vitamin D on endothelial repair and function...
February 26, 2015: Lancet
Hongying Kuang, Susan Jin, Karl R Hansen, Michael P Diamond, Christos Coutifaris, Peter Casson, Gregory Christman, Ruben Alvero, Hao Huang, G Wright Bates, Rebecca Usadi, Scott Lucidi, Valerie Baker, Nanette Santoro, Esther Eisenberg, Richard S Legro, Heping Zhang
STUDY QUESTION: Can we build and validate predictive models for ovulation and pregnancy outcomes in infertile women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: We were able to develop and validate a predictive model for pregnancy outcomes in women with PCOS using simple clinical and biochemical criteria particularly duration of attempting conception, which was the most consistent predictor among all considered factors for pregnancy outcomes. WHAT IS KNOWN ALREADY: Predictive models for ovulation and pregnancy outcomes in infertile women with polycystic ovary syndrome have been reported, but such models require validation...
September 2015: Human Reproduction
Hari Shanker Sharma, Eugene A Kiyatkin, Ranjana Patnaik, José Vicente Lafuente, Dafin F Muresanu, Per-Ove Sjöquist, Aruna Sharma
In this study, we examined the influence of cold and hot environments on methamphetamine (METH) neurotoxicity in both drug-naive rats and animals previously exposed to different types of nanoparticles (NPs). Since METH induces oxidative stress, we also examined how a potential chain-breaking antioxidant H-290/51 (Astra-Zeneca, Mölndal, Sweden) affects METH-induced neurotoxicity. Exposure of drug-naive rats to METH (9 mg/kg, s.c.) at 4, 21, or 34 °C for 3 h resulted in breakdown of the blood-brain barrier (BBB), brain edema, and neuronal injuries, which all differed in severity depending upon ambient temperatures...
October 2015: Molecular Neurobiology
Adriano Henney, Hannah Coaker
Adriano Henney speaks to Hannah Coaker, Commissioning Editor. After achieving a PhD in medicine and spending many years in academic research in the field of cardiovascular disease, Adriano Henney was recruited by Zeneca Pharmaceuticals from a British Heart Foundation Senior Fellowship, where he led the exploration of new therapeutic approaches in atherosclerosis, specifically focusing on his research interests in vascular biology. Following the merger with Astra to form AstraZeneca, Henney became responsible for exploring strategic improvements to the company's approaches to pharmaceutical target identification and the reduction of attrition in early development, directing projects across research sites and across functional project teams in the USA, Sweden and the UK...
2014: Future Medicinal Chemistry
Helgo Magnussen, Bernd Disse, Roberto Rodriguez-Roisin, Anne Kirsten, Henrik Watz, Kay Tetzlaff, Lesley Towse, Helen Finnigan, Ronald Dahl, Marc Decramer, Pascal Chanez, Emiel Wouters, Peter Calverley
SESSION TITLE: COPD TreatmentSESSION TYPE: Original Investigation SlidePRESENTED ON: Sunday, October 26, 2014 at 01:30 PM - 03:00 PMPURPOSE: The WISDOM study demonstrated ICS may be successfully withdrawn in patients receiving LAMA+LABA without significantly increasing COPD exacerbation risk (Chest 2014). We report change in FEV1 and symptoms.METHODS: All patients in the 12-month, double-blind, parallel-group, active-controlled WISDOM study (NCT00975195) received triple therapy (tiotropium 18 µg QD, salmeterol 50 µg BID, and fluticasone 500 µg BID) for a 6-week run-in period...
October 1, 2014: Chest
Stephen Rennard, Gary Ferguson, Edward Kerwin, Ludmyla Rekeda, Esther Garcia Gil
SESSION TITLE: COPD LAMA/LABASESSION TYPE Original Investigation SlidePRESENTED ON: Monday, October 27, 2014 at 01:30 PM - 02:30 PMPURPOSE: To assess long-term safety and efficacy of aclidinium bromide (AB) in moderate to severe COPD patients.METHODS: In this open-label, 40-week extension study, patients completing a 12-week double-blind lead-in trial (ACCORD II) were transitioned from randomized treatment (twice-daily [BID] placebo [PBO], AB 200µg, or AB 400µg) to AB 400µg BID. Safety, the primary outcome, was assessed via adverse events (AEs) of new or increased intensity during this extension study...
October 1, 2014: Chest
Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaz Flezar, Jacques Hébert, Anthony Veale, Lars Groenke, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, Stella Waitere-Wijker, Lorcan McGarvey
COPD Treatment PostersSESSION TYPE: Original Investigation PosterPRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PMPURPOSE: Tiotropium, a long-acting muscarinic antagonist, has recently been assessed in fixed-dose combination (FDC) with olodaterol, a once-daily, long-acting β2-agonist, for treatment of chronic obstructive pulmonary disease (COPD). We present pooled safety data from two pivotal, replicate, Phase III studies assessing efficacy and safety of FDCs of tiotropium and olodaterol(T+O) delivered via Respimat® inhaler in patients with GOLD stage 2-4 COPD...
October 1, 2014: Chest
Florin Mihaltan, Dragos Ungureanu
SESSION TITLE: COPD Diagnosis and Evaluation Posters IISESSION TYPE: Original Investigation PosterPRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PMPURPOSE: Patient-perceived COPD symptoms vary over the day and the week with impact on daily activities, morning being the worst time of day. The study aimed to identify the correlation between patient perceptions of their ability to perform morning activities and the general health status visual scale, as assessed by the physician during physical examination...
October 1, 2014: Chest
Thomas Siler, Edward Kerwin, Ana Sousa, Alison Donald, Rehan Ali, Alison Church
Late-Breaking AbstractsSESSION TYPE: Original Investigation SlidePRESENTED ON: Tuesday, October 28, 2014 at 08:45 AM - 10:00 AMPURPOSE: Umeclidinium (UMEC) is a long-acting muscarinic antagonist approved in the US and EU for maintenance treatment of chronic obstructive pulmonary disease (COPD). Fluticasone furoate/vilanterol (FF/VI; combination inhaled corticosteroid [ICS] + long-acting beta2 agonist [LABA]) is indicated for long-term, once-daily maintenance treatment of airflow obstruction in COPD. These two replicate studies evaluated efficacy and safety of UMEC added to FF/VI in patients with COPD...
October 1, 2014: Chest
Gary W K Wong, Bert Brunekreef, Philippa Ellwood, H Ross Anderson, M Innes Asher, Julian Crane, Christopher K W Lai
BACKGROUND: Indoor air pollution from a range of household cooking fuels has been implicated in the development and exacerbation of respiratory diseases. In both rich and poor countries, the effects of cooking fuels on asthma and allergies in childhood are unclear. We investigated the association between asthma and the use of a range of cooking fuels around the world. METHODS: For phase three of the International Study of Asthma and Allergies in Childhood (ISAAC), written questionnaires were self-completed at school by secondary school students aged 13-14 years, 244,734 (78%) of whom were then shown a video questionnaire on wheezing symptoms...
July 2013: Lancet Respiratory Medicine
Gwenaelle Gravis, Patricia Marino, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre, Fréderic Rolland, Christine Théodore, Gael Deplanque, Jean Marc Ferrero, Damien Pouessel, Loïc Mourey, Philippe Beuzeboc, Sylvie Zanetta, Muriel Habibian, Jean François Berdah, Jerome Dauba, Marjorie Baciuchka, Christian Platini, Claude Linassier, Jean Luc Labourey, Jean Pascal Machiels, Claude El Kouri, Alain Ravaud, Etienne Suc, Jean Christophe Eymard, Ali Hasbini, Guilhem Bousquet, Michel Soulie, Karim Fizazi
BACKGROUND: Toxicity, which is a key parameter in the evaluation of cancer treatments, can be underestimated by clinicians. We investigated differences between patients and physicians in reporting adverse events of androgen deprivation therapy (ADT) with or without docetaxel in a multicentre phase III trial in non-castrate metastatic prostate cancer. METHODS: The 385 patients included were invited to complete a 26-symptom questionnaire 3 and 6 months after the start of treatment, among which eighteen symptoms were also assessed by physicians, reported in medical records and graded using the Common Toxicity Criteria of the National Cancer Institute...
March 2014: European Journal of Cancer
Morgan Le Guen, Stanislas Grassin-Delyle, Camille Cornet, Antoine Genty, Thierry Chazot, Dominique Dardelle, Ngai Liu, Jean-François Dreyfus, Jean-Xavier Mazoit, Philippe Devillier, Jean-Claude Alvarez, Daniel I Sessler, Marc Fischler
BACKGROUND: Several commercial formulations of propofol are available. The primary outcome of this study was the required dose of propofol alone or combined with lidocaine to achieve induction of general anesthesia. METHODS: This multicenter, double-blinded trial randomized patients (American Society of Anesthesiologists physical status I-III) just before elective surgery with the use of a computer-generated list. Three different propofol 1% formulations-Diprivan (Astra-Zeneca, Cheshire, United Kingdom), Propoven (Fresenius-Kabi AG, Bad Homburg, Germany), and Lipuro (B-Braun, Melshungen AG, Germany)-were compared with either placebo (saline solution) or lidocaine 1% mixed to the propofol solution...
February 2014: Anesthesiology
Nicola Hanania, Jill Karpel, Udo-Michael Goehring, Manja Brose, Dirk Bredenbroker, Hassan Lakkis, Paul Rowe, Leonardo Fabbri
SESSION TYPE: COPD: Safety and Effectiveness of Newer TherapiesPRESENTED ON: Tuesday, October 23, 2012 at 02:45 PM - 04:15 PMPURPOSE: Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Improvement in lung function has also been noted with roflumilast treatment. This analysis examined changes in lung function among COPD subjects from a pool of seven 6-month roflumilast studies.METHODS: Data were pooled from seven 6-month randomized, placebo-controlled studies in subjects with moderate-to-severe COPD treated with roflumilast 500μg...
October 1, 2012: Chest
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"